Immunology · IL-5Regulatory Approvalregulatorymid-term

FDA Accepts Supplement Application for Depemokimab by GlaxoSmithKline

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

GSK7 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/21/2026, 6:33:02 PM

Assessment confidence: 56% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The FDA's acceptance of the supplemental application for Depemokimab signifies a potential shift in the competitive landscape of IL-5 therapies. This could impact market dynamics and necessitate strategic adjustments from competitors in the immunology sector. Regulatory context from FDA (FDA AP — EXDENSUR (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should prepare for potential market entry and competitive positioning strategies related to IL-5 therapies. The strongest clinical anchor is Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD) (ClinicalTrials.gov), moderate corpus alignment. In Immunology · IL-5, 8 regulatory and 2 competitive items passed relevance filtering for GSK.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for TZIELD (Teplizumab) Supplement (Humanexa Signals) — mechanism alignment (io ). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This acceptance may enhance GSK's position in the immunology market, particularly in therapies targeting IL-5.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — EXDENSUR (SUPPL) (FDA). Entity match (depemokimab); Regulatory pathway relevance (bla). The acceptance of the supplemental application indicates a step towards potential approval, which could affect compliance and labeling strategies for similar products.

Key Risks

Elevated medium regulatory exposure for GSK could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, Depemokimab could capture market share from existing IL-5 therapies, influencing revenue streams for both GSK and its competitors.
Portfolio teams should prepare for potential market entry and competitive positioning strategies related to IL-5 therapies.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for the review process and any subsequent approval announcements.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — EXDENSUR (SUPPL)
FDAhigh relevance
Entity match (depemokimab); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — ENSPRYNG (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View source
Investigational New Drug (IND) Application
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA AP — MALARONE PEDIATRIC (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — TRETINOIN (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — ZYRTEC HIVES (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — GADOBUTROL (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Efficacy of Vitamin D Supplementation to Sustain Performance Outcomes
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Near-Infrared Spectroscopy, Acute Taurine Supplementation, and Isolated Muscular Endurance and Fatigue Resistance in Young Healthy Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Discovering Determinants of Food Intake by Application of Artificial Intelligence to Complex, High-Dimensional Data
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for TZIELD (Teplizumab) Supplement
Humanexa Signalshigh relevance
Mechanism alignment (IO )
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The application of growth factors in bone tissue engineering delivery systems and collaborative innovation strategies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

GSK
Depemokimab

Commercial impact

medium

If approved, Depemokimab could capture market share from existing IL-5 therapies, influencing revenue streams for both GSK and its competitors.

Regulatory impact

medium

The acceptance of the supplemental application indicates a step towards potential approval, which could affect compliance and labeling strategies for similar products.

What to watch

Monitor the timeline for the review process and any subsequent approval announcements.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.